Key Drivers
- Stronger Profitability
- Debt Reduction
- Negative Equity
AIAI Summary
IRWD's strong LINZESS-funded cash generation supports a valuation-sensitive hold/watch stance, but investors should avoid treating it as a durable pharmaceutical franchise until LINZESS sustains growth through 2029 and apraglutide's STARS-2 validates a replacement engine.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Stronger Profitability
- •Debt Reduction
- •Negative Equity
IRWD shows sharply improved profitability, cash flow, liquidity, and debt reduction, but negative equity and retained losses remain significant risks requiring sustained earnings.
Price Behavior
Key Price Behavior Insights:
- •Above-average positioning
- •Resistance ceiling
- •Buyers at support
IRWD's recovery above its moving average is constructive, but repeated reversals at $4.36–$4.42 keep the outlook speculative until a decisive breakout above $4.42.
Recovery stalled after repeated reversals near resistance
Sentiment & News
Key News Insights:
- •Earnings beat
- •Guidance raised
- •Trial risk
Ironwood beat earnings estimates, raised 2026 guidance on stronger LINZESS demand, and advanced apraglutide's Phase III trial, though revenue missed expectations and patent-expiry and trial risks remain.
The update is broadly positive but leaves the stock exposed to apraglutide's binary outcome and LINZESS's 2029 patent cliff
Similar Companies in Healthcare
Other companies in the same sector with AI ratings